August 25, 2021
Emerging Oncology Company Seeks Key Opinion Leader Engagement for Novel Technology
An emerging oncology company requested Kineticos’ support to establish a development path for their novel clinically predictive technology. The sponsor needed to understand the technology’s value and potential role in clinical development and requested that Kineticos engage oncology key opinion leaders (KOLs).
Kineticos started by enhancing the sponsor’s current presentation to ensure the technology was positioned as compelling and first in class. Subsequently, a discussion guide designed to extract critical strengths, weaknesses, and potential applications was developed.
Understanding what information was most relevant to the sponsor, Kineticos identified, recruited, and conducted interviews with ten KOLs with direct experience designing oncology trials.
- Updated presentation for positioning technology
- A discussion guide for the technology
- Interviews with ten KOLs
As a result of the KOL interviews, the sponsor obtained a nuanced and thorough understanding of the needs of potential partners and patients concerning their technology. The KOLs also provided validation of interest in their technology from the scientific, medical, and biopharma communities. Kineticos was retained to support facilitating partnering meetings with a very targeted list of potential pharmaceutical collaborators.